Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement · Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma · Recurrent ALK-Positive Large B-Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation · Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type · Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Recurrent Grade 3b Follicular Lymphoma · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified · Recurrent Intravascular Large B-Cell Lymphoma · Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type · Recurrent Primary Mediastinal Large B-Cell Lymphoma · Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma · Recurrent Transformed Non-Hodgkin Lymphoma · Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · Refractory ALK-Positive Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation · Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type · Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Refractory Grade 3b Follicular Lymphoma · Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified · Refractory Intravascular Large B-Cell Lymphoma · Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type · Refractory Primary Mediastinal Large B-Cell Lymphoma · Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma · Refractory Transformed Non-Hodgkin Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Javier L. Munoz, MD, MBA)Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Muhamad Alhaj Moustafa, MD, MS)Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Mina Hanna, MD)Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Amrit B. Singh, MBBS)Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Claire Tiger, MD, PhD)Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Eyad S. Al-Hattab, MD)Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015Contact: Principal Investigator (Scott H. Okuno, MD)
Study leads
Claire Tiger, MD, PhD
Principal Investigator
Mayo Clinic